Syqe Medical

Syqe is an innovative MedTech company that developed a breakthrough technology for the administration of medical cannabis by inhalation. The SyqeAir Inhaler is a unique platform that enables physicians and patients to manage cannabis treatment safely and effectively, in compliance with the principles of the standard of care of metered dosing, lowest effective dose, and safety of use. A personalized dose for fast reduction in pain intensity and improvement in sleep quality with minimum adverse effects to establish a daily routine and improve the quality of life alongside the illness. With each inhalation, a consistent and metered amount of THC is released from a raw medical cannabis inflorescence with a full, uniform, and consistent spectrum of the active ingredients. The cannabis is sealed in a designated cartridge, which is loaded securely into the Inhaler, ready for use. The cartridge contains 60 VaporChips (each the size of a sim card), and each VaporChip contains a uniform amount of raw cannabis inflorescence grown in compliance with GMP’s strict production requirements.

Syqe Medical has raised $72.65M in total funding across 3 rounds. The company is currently at the Mature stage. Key investors include PRM Holdings Fund, Shavit Capital Fund, OurCrowd.

Syqe Medical was founded in 2011 by Perry Davidson (Founder & CEO).

Syqe Medical operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Medical Cannabis, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Raw Materials, Semiconductors & Electronics. Target customers: Healthcare & Life Sciences, Healthcare, Patients.

Syqe Medical is based in HaThiya 14, Tel Aviv-Yafo, Israel, Center District.